About Adolor
Adolor is a Healthcare company based in Exton (United States) founded in 1993, and was acquired by Cubist Pharmaceuticals in October 2011. Prescription pain and management products are developed and commercialized. Its chief executive, as recorded, is Michael Dougherty. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Adolor Corporation. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
Adolor Corporation is focused on the discovery, development, and commercialization of prescription pain and pain-management products. Its first approved product in US is ENTEREG (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The Companys lead development program compound is ADL5945, a novel mu-opioid receptor antagonist being developed for chronic OIC. Also has several earlier-stage compounds under development for the management of pain and CNS disorders.
- Headquarters Exton, United States
- Stage Public
- SectorsHealthcare
- Website adolor.com
- Social LinkedIn
- Acquired by Cubist Pharmaceuticals (Oct 2011)
- Legal Name Adolor Corporation
- Investors
- Acquired byCubist Pharmaceuticals
(Oct 2011)
Investors in Adolor
Adolor has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Cubist Pharmaceuticals.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pharmaceuticals for acute care bacterial infections are developed and commercialized. | 1993 | cubist.com | Lexington, United States |
Investor details for Adolor
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Adolor
1 people are tracked at Adolor (1 in leadership).
| Name | Role | Group |
|---|---|---|
Michael Dougherty | CEO | Leadership |
Complete people profiles for Adolor
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Adolor
3 dated milestones of Adolor across 18 years, from founding to its latest funding, stage changes and deals.
- Founded Adolor is founded.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Cubist Pharmaceuticals.
Competitors of Adolor
Adolor has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of Adolor
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as Adolor (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Adolor
Adolor was founded in 1993.
Adolor is headquartered in Exton, United States. It is registered at Exton, Pennsylvania, United States.
Michael Dougherty is the CEO of Adolor, as recorded in our data.
Adolor Corporation is focused on the discovery, development, and commercialization of prescription pain and pain-management products. Its first approved product in US is ENTEREG (alvimopan), which is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. The Companys lead development program compound is ADL5945, a novel mu-opioid receptor antagonist being developed for chronic OIC. Also has several earlier-stage compounds under development for the management of pain and CNS disorders.
Adolor's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
Adolor has 1 investor. Key investors include Cubist Pharmaceuticals.
Adolor operates through Adolor Corporation.
Yes. Adolor was acquired by Cubist Pharmaceuticals in October 2011.